research Suety and Spreading-Stromal Hyperplasia and Hyperthecosis Ovary
These ovarian conditions cause high testosterone levels.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Ovarian Hemangioma: a rare entity
Ovarian hemangioma is a rare, benign tumor that can be treated effectively with surgical removal.
research Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia
Gender-affirming hormone therapy improves mental health and gender incongruence but requires careful management of cardiovascular and cancer risks.
research Histopathological Findings and Proliferative Activity of Canine Sebaceous Gland Tumours with a Predominant Reserve Cell Population
High proliferative activity and peripheral invasion indicate malignancy in canine sebaceous gland tumors; the term 'epithelioma' should be updated for clarity.
research Immunohistochemical Pattern of CD34 Distribution in Different Types of Basal Cell Carcinoma and in Peritumoral Skin
CD34 is absent in most basal cell carcinoma cells but present in surrounding skin.
research The investigation and management of hirsutism
The document says that hirsutism in women usually needs hair removal and hormone treatment to manage symptoms and improve well-being.
research VEGF165 modulates proliferation, adhesion, migration and differentiation of cultured human outer root sheath cells from central hair follicle epithelium through VEGFR-2 activation in vitro
VEGF165 influences hair follicle cell growth and movement through VEGFR-2 activation.
research Visual Vignette
The woman's symptoms and tests suggest her adrenal glands are producing too many male hormones.
research Testicular Seminoma in a Transgender Woman: A Case Report
Transgender women can still get testicular cancer, so proper screening is important.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.